What question did this study set out to answer?

To evaluate the clinical efficacy and safety of luspatercept in adults with β-thalassemia requiring transfusions.

June 27, 2026Annals of HematologyOpen Access

Outcomes with luspatercept in patients with β-thalassemia: a systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

NBNihal Babiker EAEslam Abady HSHafsa Shahid

Discussion

Member takes

Overview

Randomized trial demonstrates luspatercept effectively reduces transfusion needs in adults with β-thalassemia, suggesting a viable therapeutic option.

Key Points

To evaluate the clinical efficacy and safety of luspatercept in adults with β-thalassemia requiring transfusions.
Conducted a systematic review and meta-analysis of randomized controlled trials.
Included English-language RCTs published up to May 2025.
Analyzed transfusion burden, hemoglobin response, and adverse events in 608 patients.
Luspatercept achieved a ≥ 33% reduction in RBC transfusion burden in 58% of patients (95% CI: 0.33–0.79).
Transfusion independence was reached in 36% of patients (95% CI: 0.13–0.69).
Common adverse events included headache (32%), bone pain (33%), and grade ≥ 3 adverse events occurred in 21% (95% CI: 0.09–0.41).

Cite This Study

Babiker et al. (2026) studied this question.

synapsesocial.com/papers/6a3f6922aea7db3c1953ff7e https://doi.org/10.1007/s00277-026-07151-5

View Full Paper

Ask AI

Bookmark

June 27, 2026Annals of HematologyOpen Access

Outcomes with luspatercept in patients with β-thalassemia: a systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

NBNihal Babiker EAEslam Abady HSHafsa Shahid

Discussion

Member takes

Overview

Randomized trial demonstrates luspatercept effectively reduces transfusion needs in adults with β-thalassemia, suggesting a viable therapeutic option.

Key Points

To evaluate the clinical efficacy and safety of luspatercept in adults with β-thalassemia requiring transfusions.
Conducted a systematic review and meta-analysis of randomized controlled trials.
Included English-language RCTs published up to May 2025.
Analyzed transfusion burden, hemoglobin response, and adverse events in 608 patients.
Luspatercept achieved a ≥ 33% reduction in RBC transfusion burden in 58% of patients (95% CI: 0.33–0.79).
Transfusion independence was reached in 36% of patients (95% CI: 0.13–0.69).
Common adverse events included headache (32%), bone pain (33%), and grade ≥ 3 adverse events occurred in 21% (95% CI: 0.09–0.41).

Cite This Study

Babiker et al. (2026) studied this question.

synapsesocial.com/papers/6a3f6922aea7db3c1953ff7e https://doi.org/10.1007/s00277-026-07151-5

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark